Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Tocilizumab
Questions discussed in this category
How would you approach a patient with GCA who develops necrotizing fasciitis and then flares because they are off of tocilizumab?
How would you treat? Would you view tocilizumab as an option in the future?
1 Answer available
What is your approach to management of elevated liver enzymes in patients who recently started treatment with tocilizumab?
1 Answer available
How do you manage a patient with giant cell arteritis treated with weekly tocilizumab and low dose glucocorticoid who develops sudden vision loss?
2 Answers available
How long do you continue steroid-sparing agents such as tocilizumab for GCA once the disease is in remission off steroids?
1 Answer available
What is your approach to managing abnormal lipids in a patient on tocilizumab?
1 Answer available
Are you recommending tocilizumab for any COVID-19 patients?
Current guidelines do not support its use, but the EMPACTA trial suggests it may be effective in a subpopulation of patients.
1 Answer available
At what point in GCA management do you typically introduce tocilizumab?
2 Answers available
Is there a role for tocilizumab in treatment of polymyalgia rheumatica in patients who do not have features of giant cell arteritis or rheumatoid arthritis?
1 Answer available
Are subcutaneous RA therapies less effective in obese patients?
1 Answer available
17339
14961
12639
8388
9621
8967
8479
7868
7885
Papers discussed in this category
,
Brief Report: A Prospective Open-Label Phase IIa Trial of Tocilizumab in the Treatment of Polymyalgia Rheumatica.
Clin. Rheumatol., 2017 Aug 18
Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis.
Ann Intern Med, 2020 Sep 22
Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis : A Cohort Study.
N Engl J Med,
Trial of Tocilizumab in Giant-Cell Arteritis.
Lancet, 2016 Mar 04
Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.
N Engl J Med, 2020 Dec 10
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.
N Engl J Med, 2020 Dec 17
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.
Arthritis Res Ther, 2021 Mar 22
Vision loss in patients with giant cell arteritis treated with tocilizumab.
Related Topics
Rheumatology
Internal Medicine
Vasculitis
General Rheumatology
GCA
Large vessel vasculitis
Giant cell arteritis
COVID-19
COVID-19 virus
Biologics